Product Images Dimethyl Fumarate

This is a graph showing the percentage of subjects with confirmed progression of disability over time in a study using a placebo and dimethyl fumarate delayed-release as treatments. The study defines confirmed progression of disability as at least a 10 point increase on the EDSS from a baseline EDSS of >= 10 confirmed for 12 weeks or at least 15 point increase on the EDSS from a baseline EDSS of 0 confirmed for 12 weeks.*

This is a description of a medication with the National Drug Code 69236-1318-4 that contains 120g of dimethyl fumarate in each delayed-release capsule. The usual dosage requires taking two capsules by mouth per day. The capsules should be stored between 20° and 25°C (66° to 77°F), with excursions permitted between 15° and 30°C (59° to 86°F). It is important to protect the medication from light and to store it in its original container. The medication is made by Annel Pharmaceuticals PL L and is distributed by Amneal Pharmaceuticals LLC in Bridgewater, N 08807, with a manufacturing license number of G/25/1941. The information is dated as of May 2020.*

Dimethyl Fumarate Delayed-Release Capsules are available in a pack of 14 capsules. Each capsule contains 120 mg of dimethyl fumarate which is used for certain medical conditions. The usual dosage is one capsule taken orally twice a day. The package insert should be referred to for administering and dosage information. The medicine should be stored between 20°C to 25°C (66° to 77°F), and needs to be protected from light. The capsule needs to be swallowed whole and the medicine should be dispensed only in the original package. This particular medicine was manufactured by Amneal Pharmaceuticals Pvt Ltd in India and distributed by Amneal Pharmaceuticals LLC located in Bridgewater, NJ, USA.*

This text describes a medication with the NDC code 69238-1319.6 that comes in the form of delayed-release capsules containing 240 mg of dimethyl fumarate. The recommended dosage is one capsule taken orally twice a day. The medication should be stored in the original container at controlled room temperature and protected from light. The medication is manufactured by Amneal Pharmaceuticals Pvt Ltd, located in India, and distributed by Amneal Pharmaceuticals LLC in Bridgevater, NJ.*

Dimethyl Fumarate Delayed-Release Capsules are indicated for the treatment of multiple sclerosis. Each capsule contains dimethyl fumarate and is taken orally, twice a day. The medication is manufactured by Amneal Pharmaceuticals in India and distributed by Amneal Pharmaceuticals LLC in Bidgevater, NJ. The capsules should be stored at room temperature and protected from light. It is important to swallow the capsule whole and to use the original package for dispensing.*

Each capsule of this medication contains 120 mg of dimethyl fumarate. It is intended to be taken orally, once a day. This is a starter dose of 120 mg, and the medication comes in delayed-release capsules. The container should be protected from light. Full dosage instructions are unavailable.*

This is a description of a drug with NDC number 6923816268. Each capsule contains dimethyl fumarate 240 g. The recommended dosage is one capsule taken orally twice a day. The drug should be stored in its original container and protected from light at a temperature range of 20 to 26°C (66 to 77°F). It has a delayed-release formula and should be stored at controlled room temperature. The drug was manufactured by Amneal Pharmaceuticals Pt. Ltd and distributed by Amneal Pharmaceuticals LLC.*

This is a product description for a 30-day starter pack of Dimethyl Fumarate Delayed-Release Capsules, with package contents of 120mg and 240mg doses. The usual dosage is one capsule taken orally twice a day. The product is manufactured by Amneal Pharmaceuticals and should be stored in a controlled room temperature of 20-25°C. The back panel provides instructions for dosage and administration for use.*